Summary
Global Markets Direct’s, ‘Atherosclerosis - Pipeline Review, H1 2016’, provides an overview of the Atherosclerosis pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Atherosclerosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Atherosclerosis and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Atherosclerosis
- The report reviews pipeline therapeutics for Atherosclerosis by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Atherosclerosis therapeutics and enlists all their major and minor projects
- The report assesses Atherosclerosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Atherosclerosis
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Atherosclerosis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Atherosclerosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
Ache Laboratorios Farmaceuticos S/A
advanceCor GmbH
AFFiRiS AG
Amgen Inc.
Arisaph Pharmaceuticals, Inc.
Artery Therapeutics, Inc.
AstraZeneca Plc
Athera Biotechnologies AB
AtheroNova Inc.
Bayer AG
Campus Technologies Freiburg GmbH
Cardax Pharmaceuticals, Inc.
Cerenis Therapeutics Holding SA
ChemoCentryx, Inc.
CohBar, Inc.
Daewoong Pharmaceutical Co., Ltd.
Daiichi Sankyo Company, Limited
DoNatur GmbH
Dybly AG
Exicure, Inc.
GenKyoTex S.A.
Jenrin Discovery, Inc.
Johnson & Johnson
KineMed, Inc.
Kowa Company, Ltd.
La Jolla Pharmaceutical Company
Lead Discovery Center GmbH
Merck & Co., Inc.
MI.TO. Technology S.r.L.
Omeros Corporation
OPKO Health, Inc.
Otsuka Holdings Co., Ltd.
Resverlogix Corp.
The Medicines Company
Therapix Biosciences Ltd
Tolerys SA
Vascular Biogenics Ltd.
Vericel Corporation
Vitae Pharmaceuticals, Inc.
XBiotech USA, Inc.
'
Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Atherosclerosis Overview 11
Therapeutics Development 12
Pipeline Products for Atherosclerosis - Overview 12
Pipeline Products for Atherosclerosis - Comparative Analysis 13
Atherosclerosis - Therapeutics under Development by Companies 14
Atherosclerosis - Therapeutics under Investigation by Universities/Institutes 18
Atherosclerosis - Pipeline Products Glance 20
Late Stage Products 20
Clinical Stage Products 21
Early Stage Products 22
Atherosclerosis - Products under Development by Companies 23
Atherosclerosis - Products under Investigation by Universities/Institutes 27
Atherosclerosis - Companies Involved in Therapeutics Development 29
Ache Laboratorios Farmaceuticos S/A 29
advanceCor GmbH 30
AFFiRiS AG 31
Amgen Inc. 32
Arisaph Pharmaceuticals, Inc. 33
Artery Therapeutics, Inc. 34
AstraZeneca Plc 35
Athera Biotechnologies AB 36
AtheroNova Inc. 37
Bayer AG 38
Campus Technologies Freiburg GmbH 39
Cardax Pharmaceuticals, Inc. 40
Cerenis Therapeutics Holding SA 41
ChemoCentryx, Inc. 42
CohBar, Inc. 43
Daewoong Pharmaceutical Co., Ltd. 44
Daiichi Sankyo Company, Limited 45
DoNatur GmbH 46
Dybly AG 47
Exicure, Inc. 48
GenKyoTex S.A. 49
Jenrin Discovery, Inc. 50
Johnson & Johnson 51
KineMed, Inc. 52
Kowa Company, Ltd. 53
La Jolla Pharmaceutical Company 54
Lead Discovery Center GmbH 55
Merck & Co., Inc. 56
MI.TO. Technology S.r.L. 57
Omeros Corporation 58
OPKO Health, Inc. 59
Otsuka Holdings Co., Ltd. 60
Resverlogix Corp. 61
The Medicines Company 62
Therapix Biosciences Ltd 63
Tolerys SA 64
Vascular Biogenics Ltd. 65
Vericel Corporation 66
Vitae Pharmaceuticals, Inc. 67
XBiotech USA, Inc. 68
Atherosclerosis - Therapeutics Assessment 69
Assessment by Monotherapy Products 69
Assessment by Combination Products 70
Assessment by Target 71
Assessment by Mechanism of Action 75
Assessment by Route of Administration 78
Assessment by Molecule Type 80
Drug Profiles 82
AEM-28 - Drug Profile 82
AG-01 - Drug Profile 84
AHRO-001 - Drug Profile 85
AHRO-002 - Drug Profile 87
AHRO-003 - Drug Profile 88
AM-0010 - Drug Profile 89
anacetrapib - Drug Profile 91
Annexin A-5 - Drug Profile 93
apabetalone - Drug Profile 95
APTA-5278 - Drug Profile 98
ARI-1778 - Drug Profile 99
Artpep-2 - Drug Profile 100
ATH-04 - Drug Profile 101
ATH-06 - Drug Profile 102
AZ-876 - Drug Profile 103
BAY-606583 - Drug Profile 104
BSN-272 - Drug Profile 105
CCX-771 - Drug Profile 106
CDX-085 - Drug Profile 107
Cell Therapy for Atherosclerosis - Drug Profile 109
Cellular Immunotherapy for Atherosclerosis - Drug Profile 110
CER-209 - Drug Profile 111
CM-7 - Drug Profile 112
COR-2 - Drug Profile 113
D-4F - Drug Profile 114
DIAS-2 - Drug Profile 115
Dipep - Drug Profile 116
Drug for Atherosclerosis - Drug Profile 117
Drug for Atherosclerosis - Drug Profile 118
Drugs to Activate TLR3 for Atherosclerosis - Drug Profile 119
DWJ-210 - Drug Profile 120
DYB-186 - Drug Profile 121
EP-80317 - Drug Profile 122
Gene Therapy for Arteriosclerosis and Endothelial Dysfunction - Drug Profile 123
Gene Therapy to Activate Follistatin for Sarcopenia and Atherosclerosis - Drug Profile 124
Gene Therapy to Activate Interleukin 10 for Atherosclerosis - Drug Profile 125
Gene Therapy to Activate Telomerase for Alzheimer’s Disease and Atherosclerosis - Drug Profile 126
Gene Therapy to Target miR-145 for Atherosclerosis - Drug Profile 127
GKT-831 - Drug Profile 128
GYY-4137 - Drug Profile 129
Humanin - Drug Profile 131
INV-88 - Drug Profile 133
ISIS-APOARx - Drug Profile 134
ITP-01 - Drug Profile 135
ixmyelocel-T - Drug Profile 136
JD-2000 Series - Drug Profile 139
JD-5000 Series - Drug Profile 140
JD-6000 Series - Drug Profile 141
K-312 - Drug Profile 142
K-877 - Drug Profile 143
KM-011 - Drug Profile 145
leucine + niacin - Drug Profile 146
LJPC-6417 - Drug Profile 147
LPC-01 - Drug Profile 148
MCS-18 - Drug Profile 149
MDCO-216 - Drug Profile 151
melittin - Drug Profile 153
Monoclonal Antibodies to Inhibit IL-1a for Myocardial Infarction and Atherosclerosis - Drug Profile 154
Monoclonal Antibody to Inhibit CD3 for Cardiovascular, CNS, Gastrointestinal, Immunological, Infectious and Metabolic Diseases - Drug Profile 155
Monoclonal Antibody to Inhibit Endothelial Lipase for Atherosclerosis - Drug Profile 157
Oligonucleotide for Hyperlipidemia and Atherosclerosis - Drug Profile 158
Oligonucleotides to Agonize SRB1 for Atherosclerosis and Lymphoma - Drug Profile 159
P-16 - Drug Profile 161
PC-mAb - Drug Profile 162
Peptides to Inhibit Calcineurin for Rheumatoid Arthritis and Atherosclerosis - Drug Profile 164
PR-15 - Drug Profile 165
Recombinant Protein for Atherosclerosis - Drug Profile 167
Recombinant Protein for Atherosclerosis and Hepatic Steatosis - Drug Profile 168
Recombinant Protein for Cardiovascular Diseases - Drug Profile 170
Recombinant Proteins to Inhibit Serine Protease for Thrombosis, Ischemic Stroke and Atherosclerosis - Drug Profile 171
rPAI-123 - Drug Profile 172
Small Molecule for Atherosclerosis - Drug Profile 173
Small Molecule for Atherosclerosis - Drug Profile 174
Small Molecule for Atherosclerosis and Insulin Resistance - Drug Profile 175
Small Molecule to Activate NF-E2 Related Factor 2 for Central Nervous System, Metabolic Disorders, Cardiovascular and Ophthalmology - Drug Profile 176
Small Molecule to Agonize Liver X Receptor for Atherosclerosis - Drug Profile 177
Small Molecule to Inhibit IKK and TBK1 for Cardiovascular, Gastrointestinal and Metabolic Disorders - Drug Profile 178
Small Molecule to Inhibit microRNA-223 for Atherosclerosis - Drug Profile 179
Small Molecule to Target GPR132 for Cardiovascular Diseases - Drug Profile 180
Small Molecule to Target GPR176 for Atherosclerosis - Drug Profile 181
Small Molecules for Atherosclerosis - Drug Profile 182
Small Molecules for Atherosclerosis, Inflammation and Metabolic Disorders - Drug Profile 183
Small Molecules for Ophthalmology, Cardiovascular, CNS and Metabolic Disorders - Drug Profile 184
Small Molecules to Agonize GPR81 for Atherosclerosis and Obesity - Drug Profile 186
Small Molecules to Inhibit Chymase for Atherosclerosis - Drug Profile 187
Small Molecules to Inhibit Lipase for Atherosclerosis - Drug Profile 188
SPX-7233801 - Drug Profile 189
SR-9009 - Drug Profile 190
Stem Cell Therapy for Atherosclerosis - Drug Profile 191
Synthetic Peptide to Inhibit F11R for Atherosclerosis - Drug Profile 192
Synthetic Peptides for Cardiovascular, Gastrointestinal, Metabolic Disorders and Infectious Disease - Drug Profile 194
Synthetic Peptides for Oncology, Sepsis and Atherosclerosis - Drug Profile 196
Synthetic Peptides to Activate Apolipoprotein for Atherosclerosis and Inflammation - Drug Profile 197
Synthetic Peptides to Activate CD36 Receptor for Cardiovascular Diseases and Macular Degeneration - Drug Profile 198
Vaccine for Atherosclerosis - Drug Profile 200
Vaccine for Atherosclerosis - Drug Profile 201
Vaccine for Atherosclerosis - Drug Profile 202
VB-201 - Drug Profile 203
VTP-4 - Drug Profile 205
Atherosclerosis - Recent Pipeline Updates 206
Atherosclerosis - Dormant Projects 235
Atherosclerosis - Discontinued Products 246
Atherosclerosis - Product Development Milestones 249
Featured News & Press Releases 249
Appendix 256
Methodology 256
Coverage 256
Secondary Research 256
Primary Research 256
Expert Panel Validation 256
Contact Us 256
Disclaimer 257
List of Tables
Number of Products under Development for Atherosclerosis, H1 2016 19
Number of Products under Development for Atherosclerosis - Comparative Analysis, H1 2016 20
Number of Products under Development by Companies, H1 2016 21
Number of Products under Development by Companies, H1 2016 (Contd..1) 22
Number of Products under Development by Companies, H1 2016 (Contd..2) 23
Number of Products under Development by Companies, H1 2016 (Contd..3) 24
Number of Products under Investigation by Universities/Institutes, H1 2016 26
Comparative Analysis by Late Stage Development, H1 2016 27
Comparative Analysis by Clinical Stage Development, H1 2016 28
Comparative Analysis by Early Stage Development, H1 2016 29
Products under Development by Companies, H1 2016 30
Products under Development by Companies, H1 2016 (Contd..1) 31
Products under Development by Companies, H1 2016 (Contd..2) 32
Products under Development by Companies, H1 2016 (Contd..3) 33
Products under Investigation by Universities/Institutes, H1 2016 34
Products under Investigation by Universities/Institutes, H1 2016 (Contd..1) 35
Atherosclerosis - Pipeline by Ache Laboratorios Farmaceuticos S/A, H1 2016 36
Atherosclerosis - Pipeline by advanceCor GmbH, H1 2016 37
Atherosclerosis - Pipeline by AFFiRiS AG, H1 2016 38
Atherosclerosis - Pipeline by Amgen Inc., H1 2016 39
Atherosclerosis - Pipeline by Arisaph Pharmaceuticals, Inc., H1 2016 40
Atherosclerosis - Pipeline by Artery Therapeutics, Inc., H1 2016 41
Atherosclerosis - Pipeline by AstraZeneca Plc, H1 2016 42
Atherosclerosis - Pipeline by Athera Biotechnologies AB, H1 2016 43
Atherosclerosis - Pipeline by AtheroNova Inc., H1 2016 44
Atherosclerosis - Pipeline by Bayer AG, H1 2016 45
Atherosclerosis - Pipeline by Campus Technologies Freiburg GmbH, H1 2016 46
Atherosclerosis - Pipeline by Cardax Pharmaceuticals, Inc., H1 2016 47
Atherosclerosis - Pipeline by Cerenis Therapeutics Holding SA, H1 2016 48
Atherosclerosis - Pipeline by ChemoCentryx, Inc., H1 2016 49
Atherosclerosis - Pipeline by CohBar, Inc., H1 2016 50
Atherosclerosis - Pipeline by Daewoong Pharmaceutical Co., Ltd., H1 2016 51
Atherosclerosis - Pipeline by Daiichi Sankyo Company, Limited, H1 2016 52
Atherosclerosis - Pipeline by DoNatur GmbH, H1 2016 53
Atherosclerosis - Pipeline by Dybly AG, H1 2016 54
Atherosclerosis - Pipeline by Exicure, Inc., H1 2016 55
Atherosclerosis - Pipeline by GenKyoTex S.A., H1 2016 56
Atherosclerosis - Pipeline by Jenrin Discovery, Inc., H1 2016 57
Atherosclerosis - Pipeline by Johnson & Johnson, H1 2016 58
Atherosclerosis - Pipeline by KineMed, Inc., H1 2016 59
Atherosclerosis - Pipeline by Kowa Company, Ltd., H1 2016 60
Atherosclerosis - Pipeline by La Jolla Pharmaceutical Company, H1 2016 61
Atherosclerosis - Pipeline by Lead Discovery Center GmbH, H1 2016 62
Atherosclerosis - Pipeline by Merck & Co., Inc., H1 2016 63
Atherosclerosis - Pipeline by MI.TO. Technology S.r.L., H1 2016 64
Atherosclerosis - Pipeline by Omeros Corporation, H1 2016 65
Atherosclerosis - Pipeline by OPKO Health, Inc., H1 2016 66
Atherosclerosis - Pipeline by Otsuka Holdings Co., Ltd., H1 2016 67
Atherosclerosis - Pipeline by Resverlogix Corp., H1 2016 68
Atherosclerosis - Pipeline by The Medicines Company, H1 2016 69
Atherosclerosis - Pipeline by Therapix Biosciences Ltd, H1 2016 70
Atherosclerosis - Pipeline by Tolerys SA, H1 2016 71
Atherosclerosis - Pipeline by Vascular Biogenics Ltd., H1 2016 72
Atherosclerosis - Pipeline by Vericel Corporation, H1 2016 73
Atherosclerosis - Pipeline by Vitae Pharmaceuticals, Inc., H1 2016 74
Atherosclerosis - Pipeline by XBiotech USA, Inc., H1 2016 75
Assessment by Monotherapy Products, H1 2016 76
Assessment by Combination Products, H1 2016 77
Number of Products by Stage and Target, H1 2016 79
Number of Products by Stage and Mechanism of Action, H1 2016 83
Number of Products by Stage and Route of Administration, H1 2016 86
Number of Products by Stage and Molecule Type, H1 2016 88
Atherosclerosis Therapeutics - Recent Pipeline Updates, H1 2016 213
Atherosclerosis - Dormant Projects, H1 2016 242
Atherosclerosis - Dormant Projects (Contd..1), H1 2016 243
Atherosclerosis - Dormant Projects (Contd..2), H1 2016 244
Atherosclerosis - Dormant Projects (Contd..3), H1 2016 245
Atherosclerosis - Dormant Projects (Contd..4), H1 2016 246
Atherosclerosis - Dormant Projects (Contd..5), H1 2016 247
Atherosclerosis - Dormant Projects (Contd..6), H1 2016 248
Atherosclerosis - Dormant Projects (Contd..7), H1 2016 249
Atherosclerosis - Dormant Projects (Contd..8), H1 2016 250
Atherosclerosis - Dormant Projects (Contd..9), H1 2016 251
Atherosclerosis - Dormant Projects (Contd..10), H1 2016 252
Atherosclerosis - Discontinued Products, H1 2016 253
Atherosclerosis - Discontinued Products (Contd..1), H1 2016 254
Atherosclerosis - Discontinued Products (Contd..2), H1 2016 255
List of Figures
Number of Products under Development for Atherosclerosis, H1 2016 19
Number of Products under Development for Atherosclerosis - Comparative Analysis, H1 2016 20
Number of Products under Development by Companies, H1 2016 21
Number of Products under Investigation by Universities/Institutes, H1 2016 25
Comparative Analysis by Clinical Stage Development, H1 2016 28
Comparative Analysis by Early Stage Products, H1 2016 29
Assessment by Monotherapy Products, H1 2016 76
Number of Products by Top 10 Targets, H1 2016 78
Number of Products by Stage and Top 10 Targets, H1 2016 78
Number of Products by Top 10 Mechanism of Actions, H1 2016 82
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 82
Number of Products by Routes of Administration, H1 2016 85
Number of Products by Stage and Routes of Administration, H1 2016 85
Number of Products by Top 10 Molecule Types, H1 2016 87
Number of Products by Stage and Top 10 Molecule Types, H1 2016 87
